Status and phase
Conditions
Treatments
About
A randomized, open, drug controlled design of experiments was used to evaluate the early bactericidal activity, safety, tolerance and pharmacokinetic characteristics of JDB0131 benzenesulfonate tablet taken orally by drug sensitive pulmonary tuberculosis patients. Five groups are proposed to be set up in this test (JDB0131 benzenesulfonate 100mg BID, JDB0131 benzenesulfonate 200mg QD, JDB0131 benzenesulfonate 200mg BID, anti tuberculosis drug fixed dose composite dosage QD is determined according to the weight of the study participants, and delamanid 100mg BID)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
(Those who must meet all the selection criteria can enter the group)
Exclusion criteria
(Meet any of the following criteria will be excluded)
Primary purpose
Allocation
Interventional model
Masking
52 participants in 5 patient groups
Loading...
Central trial contact
Naihui Chu, Dr.; Mailing Huang, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal